1. Home
  2. RVLV vs CANF Comparison

RVLV vs CANF Comparison

Compare RVLV & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Revolve Group Inc.

RVLV

Revolve Group Inc.

HOLD

Current Price

$22.14

Market Cap

1.8B

ML Signal

HOLD

Logo Can-Fite Biopharma Ltd Sponsored ADR (Israel)

CANF

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

HOLD

Current Price

$3.12

Market Cap

4.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RVLV
CANF
Founded
2003
1994
Country
United States
Israel
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
4.7M
IPO Year
2018
2011

Fundamental Metrics

Financial Performance
Metric
RVLV
CANF
Price
$22.14
$3.12
Analyst Decision
Buy
Strong Buy
Analyst Count
12
2
Target Price
$29.73
$9,750.00
AVG Volume (30 Days)
777.5K
614.9K
Earning Date
05-05-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
24.64
N/A
EPS
0.86
N/A
Revenue
$1,225,682,000.00
N/A
Revenue This Year
$10.96
$2,715,455.50
Revenue Next Year
$8.01
$101.06
P/E Ratio
$26.30
N/A
Revenue Growth
8.48
N/A
52 Week Low
$16.80
$0.17
52 Week High
$31.68
$10.40

Technical Indicators

Market Signals
Indicator
RVLV
CANF
Relative Strength Index (RSI) 39.96 37.08
Support Level $22.12 $0.59
Resistance Level $22.37 $4.74
Average True Range (ATR) 0.82 0.19
MACD 0.08 -0.05
Stochastic Oscillator 36.70 15.66

Price Performance

Historical Comparison
RVLV
CANF

About RVLV Revolve Group Inc.

Revolve Group Inc is an emerging e-commerce retailer, selling women's dresses, handbags, shoes, beauty products, and incidentals across its marketplace properties, Revolve and FWRD. The platform is built to suit the "next-generation customer," emphasizing mobile commerce, influencer marketing, and occupying an aspirational but attainable luxury niche. With $1.1 billion in 2024 net sales, the firm sits just outside the top 30 apparel retailers (by sales) in the U.S, but has consistently generated robust top-line growth as the industry continues to favor digital channels. Revolve generates approximately 18% of sales from private-label offerings, while focusing on building an inventory of distinctive products from emerging fashion brands with less than $10 million in annual sales.

About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.

Share on Social Networks: